Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04951388

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

Covid19 Vaccine Clinical Trial

Official title:
A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents

Clinical Trial Summary

The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine compared to placebo in participants aged ≥ 12 to < 18 years.

Clinical Trial Description

This is a Phase II, prospective, placebo-controlled, double-blinded (investigator/site staff and participants), multi-center study; the Sponsor will be blinded until the interim analysis. Participants aged ≥ 12 to < 18 years will be enrolled. All eligible participants will be randomized to receive either MVC-COV1901 or placebo in a 6:1 ratio. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04951388
Study type Interventional
Source Medigen Vaccine Biologics Corp.
Contact
Status Completed
Phase Phase 2
Start date July 22, 2021
Completion date March 21, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT05079633 - A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults Phase 4
Completed NCT05011526 - A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults Phase 3
Completed NCT04822025 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults Phase 2
Completed NCT04818892 - Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease
Not yet recruiting NCT04730895 - Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. Phase 1/Phase 2
Completed NCT05048849 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study Phase 2
Completed NCT04765436 - PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 Phase 1
Active, not recruiting NCT04760704 - Covid-19 Vaccine Response in Elderly Subjects
Completed NCT04695652 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult Phase 2
Withdrawn NCT05029245 - IntraDermal Versus Intramuscular Comirnaty® Efficacy Study Phase 3
Completed NCT05038618 - A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study Phase 2
Completed NCT05175742 - PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine. Phase 2
Recruiting NCT04834869 - COVID-19 Vaccines Safety Tracking (CoVaST)